Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease

Craig Moskowitz, Tarun Kewalramani, Stephen D Nimer, Maria Gonzalez, Andrew D. Zelenetz, Joachim Yahalom

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Prospective randomized studies have determined that high dose therapy and autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed Hodgkin's disease (HD); however, the role of this approach in patients with primary refractory disease has been controversial. This report is an integrated analysis of 75 consecutive patients with biopsy-confirmed primary refractory HD, who were treated with high dose chemoradiotherapy (HDT) and ASCT at the Memorial Sloan Kettering Cancer Center. The patients underwent conventional dose cytoreductive chemotherapy followed by HDT and ASCT. At a median follow-up of 10 years for surviving patients, the event-free survival (EFS), progression-free survival (PFS) and overall survival (OS) rates were 45%, 49% and 48% respectively. Only chemosensitivity to standard-dose second-line chemotherapy (SDSC) predicted for a better survival, thus responding patients had an EFS, PFS and OS of 60%, 62% and 66%, respectively, versus 19%, 23% and 17% for patients who had a poor response to SDSC (P < 0.001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy.

Original languageEnglish
Pages (from-to)645-652
Number of pages8
JournalBritish Journal of Haematology
Volume124
Issue number5
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Chemoradiotherapy
Hodgkin Disease
Biopsy
Disease-Free Survival
Drug Therapy
Survival
Survival Rate
Prospective Studies
Therapeutics

Keywords

  • ASCT
  • Biopsy-proven
  • Chemosensitive
  • Hodgkin's Disease
  • Refractory

ASJC Scopus subject areas

  • Hematology

Cite this

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. / Moskowitz, Craig; Kewalramani, Tarun; Nimer, Stephen D; Gonzalez, Maria; Zelenetz, Andrew D.; Yahalom, Joachim.

In: British Journal of Haematology, Vol. 124, No. 5, 01.03.2004, p. 645-652.

Research output: Contribution to journalArticle

@article{d11d5a0bca194a3d8b1e3c0079db4cc1,
title = "Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease",
abstract = "Prospective randomized studies have determined that high dose therapy and autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed Hodgkin's disease (HD); however, the role of this approach in patients with primary refractory disease has been controversial. This report is an integrated analysis of 75 consecutive patients with biopsy-confirmed primary refractory HD, who were treated with high dose chemoradiotherapy (HDT) and ASCT at the Memorial Sloan Kettering Cancer Center. The patients underwent conventional dose cytoreductive chemotherapy followed by HDT and ASCT. At a median follow-up of 10 years for surviving patients, the event-free survival (EFS), progression-free survival (PFS) and overall survival (OS) rates were 45{\%}, 49{\%} and 48{\%} respectively. Only chemosensitivity to standard-dose second-line chemotherapy (SDSC) predicted for a better survival, thus responding patients had an EFS, PFS and OS of 60{\%}, 62{\%} and 66{\%}, respectively, versus 19{\%}, 23{\%} and 17{\%} for patients who had a poor response to SDSC (P < 0.001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy.",
keywords = "ASCT, Biopsy-proven, Chemosensitive, Hodgkin's Disease, Refractory",
author = "Craig Moskowitz and Tarun Kewalramani and Nimer, {Stephen D} and Maria Gonzalez and Zelenetz, {Andrew D.} and Joachim Yahalom",
year = "2004",
month = "3",
day = "1",
doi = "10.1111/j.1365-2141.2003.04828.x",
language = "English",
volume = "124",
pages = "645--652",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease

AU - Moskowitz, Craig

AU - Kewalramani, Tarun

AU - Nimer, Stephen D

AU - Gonzalez, Maria

AU - Zelenetz, Andrew D.

AU - Yahalom, Joachim

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Prospective randomized studies have determined that high dose therapy and autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed Hodgkin's disease (HD); however, the role of this approach in patients with primary refractory disease has been controversial. This report is an integrated analysis of 75 consecutive patients with biopsy-confirmed primary refractory HD, who were treated with high dose chemoradiotherapy (HDT) and ASCT at the Memorial Sloan Kettering Cancer Center. The patients underwent conventional dose cytoreductive chemotherapy followed by HDT and ASCT. At a median follow-up of 10 years for surviving patients, the event-free survival (EFS), progression-free survival (PFS) and overall survival (OS) rates were 45%, 49% and 48% respectively. Only chemosensitivity to standard-dose second-line chemotherapy (SDSC) predicted for a better survival, thus responding patients had an EFS, PFS and OS of 60%, 62% and 66%, respectively, versus 19%, 23% and 17% for patients who had a poor response to SDSC (P < 0.001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy.

AB - Prospective randomized studies have determined that high dose therapy and autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed Hodgkin's disease (HD); however, the role of this approach in patients with primary refractory disease has been controversial. This report is an integrated analysis of 75 consecutive patients with biopsy-confirmed primary refractory HD, who were treated with high dose chemoradiotherapy (HDT) and ASCT at the Memorial Sloan Kettering Cancer Center. The patients underwent conventional dose cytoreductive chemotherapy followed by HDT and ASCT. At a median follow-up of 10 years for surviving patients, the event-free survival (EFS), progression-free survival (PFS) and overall survival (OS) rates were 45%, 49% and 48% respectively. Only chemosensitivity to standard-dose second-line chemotherapy (SDSC) predicted for a better survival, thus responding patients had an EFS, PFS and OS of 60%, 62% and 66%, respectively, versus 19%, 23% and 17% for patients who had a poor response to SDSC (P < 0.001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy.

KW - ASCT

KW - Biopsy-proven

KW - Chemosensitive

KW - Hodgkin's Disease

KW - Refractory

UR - http://www.scopus.com/inward/record.url?scp=1542359509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542359509&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2003.04828.x

DO - 10.1111/j.1365-2141.2003.04828.x

M3 - Article

C2 - 14871252

AN - SCOPUS:1542359509

VL - 124

SP - 645

EP - 652

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -